BG Medicine Inc
OTC:BGMD
BG Medicine Inc
Research & Development
BG Medicine Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BG Medicine Inc
OTC:BGMD
|
Research & Development
-$1.8m
|
CAGR 3-Years
38%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Research & Development
-$1.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Danaher Corp
NYSE:DHR
|
Research & Development
-$1.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-6%
|
|
|
Waters Corp
NYSE:WAT
|
Research & Development
-$195.7m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Research & Development
-$454m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-4%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
BG Medicine Inc
Glance View
BG Medicine, Inc. is a life sciences company. The company is headquartered in Foxboro, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2011-02-04. The firm is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The firm's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners' automated platforms. The firm's CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
See Also
What is BG Medicine Inc's Research & Development?
Research & Development
-1.8m
USD
Based on the financial report for Dec 31, 2015, BG Medicine Inc's Research & Development amounts to -1.8m USD.
What is BG Medicine Inc's Research & Development growth rate?
Research & Development CAGR 5Y
23%
Over the last year, the Research & Development growth was 26%. The average annual Research & Development growth rates for BG Medicine Inc have been 38% over the past three years , 23% over the past five years .
